March 4, 2013 - Atlanta, GA. The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women’s health organizations, today called on US government agencies to coordinate a national agenda that will quickly and accurately answer questions about how the antiretroviral (ARV) drug Truvada can best be made available as an HIV prevention option for women at risk of HIV infection. Continue Reading...
Do you get our newsletter?
Sign up for our monthly Newsletter and get the latest info in you in box.
Learn how to recognize and deal with some of the milder, more common side effects of HIV drugs as well as some of the more serious ones.
Get information about two of the most common HIV-related brain problems: minor cognitive motor disorder and HIV-associated dementia.